These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17112623)

  • 61. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 62. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
    Geng X; Wang F; Li YG; Zhu GP; Zhang WM
    J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Selection criteria for patients with hepatocellular carcinoma in liver transplantation.
    Kaido T; Takada Y; Uemoto S
    Transplantation; 2009 Aug; 88(3):442-3; author reply 443. PubMed ID: 19667951
    [No Abstract]   [Full Text] [Related]  

  • 64. [The clinical significance of cystatin B in hepatocellular carcinoma].
    He J; Feng ZB; Wu MH
    Zhonghua Gan Zang Bing Za Zhi; 2010 Dec; 18(12):936-7. PubMed ID: 21205482
    [No Abstract]   [Full Text] [Related]  

  • 65. Recent advances in tumor markers of human hepatocellular carcinoma.
    Yoon SK
    Intervirology; 2008; 51 Suppl 1():34-41. PubMed ID: 18544946
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Early discovery of hepatocellular carcinoma].
    Tanikawa K
    Nihon Naika Gakkai Zasshi; 1997 Mar; 86(3):402-5. PubMed ID: 9198619
    [No Abstract]   [Full Text] [Related]  

  • 67. The new generation of hepatocellular markers.
    Mount S
    Cancer Cytopathol; 2012 Aug; 120(4):217-9. PubMed ID: 22760992
    [No Abstract]   [Full Text] [Related]  

  • 68. The predictive ability of serum alpha-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance.
    Huo TI; Hsia CY; Chu CJ; Huang YH; Lui WY; Wu JC; Lee PC; Chi CW; Lee SD
    J Surg Oncol; 2007 Jun; 95(8):645-51. PubMed ID: 17530668
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hepatocellular carcinoma: paving the road for further developments.
    Bruix J
    Semin Liver Dis; 2014 Nov; 34(4):361. PubMed ID: 25369298
    [No Abstract]   [Full Text] [Related]  

  • 70. The use of epigenetic biomarkers for preclinical detection of hepatocellular carcinoma: potential for noninvasive screening of high-risk populations.
    Rivenbark AG; Coleman WB
    Clin Cancer Res; 2007 Apr; 13(8):2309-12. PubMed ID: 17438087
    [No Abstract]   [Full Text] [Related]  

  • 71. Use of common seric tumor markers in patients with solid cancers.
    Gara S; Boussen H; Ghanem A; Guemira F
    Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tumour markers of hepatocellular carcinoma.
    Kew MC
    J Gastroenterol Hepatol; 1989; 4(4):373-84. PubMed ID: 2562350
    [No Abstract]   [Full Text] [Related]  

  • 73. Rivanol precipitation technique for the detection of alpha-feto-protein.
    Mody NJ; Vogel CL; Patel IR; McIntire KR
    J Lab Clin Med; 1972 Jul; 80(1):125-33. PubMed ID: 4338276
    [No Abstract]   [Full Text] [Related]  

  • 74. Des-gamma-carboxy prothrombin (DCP) ratio is a useful prognostic tumor marker for single nodule hepatocellular carcinoma (HCC).
    Murakami N; Tamano M; Yoneda M; Sugaya H; Hiraishi H
    Hepatogastroenterology; 2008; 55(81):197-201. PubMed ID: 18507106
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Alpha feto-protein in the diagnosis of primary hepatocarcinoma in Salisbury.
    Ashworth TG
    Cent Afr J Med; 1974 Jan; 20(1):5-7. PubMed ID: 4376463
    [No Abstract]   [Full Text] [Related]  

  • 76. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
    Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
    J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A fetal serum protein in a new role.
    N Engl J Med; 1968 May; 278(18):1016. PubMed ID: 4171302
    [No Abstract]   [Full Text] [Related]  

  • 78. [Serum arginase activity in patients with liver cirrhosis and hepatocellular carcinoma].
    Chrzanowska A; Mielczarek-Puta M; Skwarek A; Krawczyk M; Barańczyk-Kuźma A
    Wiad Lek; 2007; 60(5-6):215-8. PubMed ID: 17966882
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma.
    Iizuka N; Sakaida I; Moribe T; Fujita N; Miura T; Stark M; Tamatsukuri S; Ishitsuka H; Uchida K; Terai S; Sakamoto K; Tamesa T; Oka M
    Anticancer Res; 2006; 26(6C):4713-9. PubMed ID: 17214331
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
    Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A
    Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.